tbuckley/cabot-search huggingface dataset:
Abstract 212: Infrared spectral diagnosis for predictive cancer medicine: application to the early diagnosis and prognosis of preinvasive bronchial intraepithelial lesions
Authors: Vincent D. Gaydou, Myriame Polette, Cyril Gobinet, Claire Kileztky, Michel Manfait, Philippe Birembaut, Olivier Piot
Journal: Cancer Research (2015)

Abstract This study concerns the development of a new imaging diagnostic tool for bronchial cancer. This malignancy is a wide-spread cancer in the world, with an increasing incidence. Our objective is to assess the potential of infrared (IR) spectroscopy in the early diagnosis of the bronchial cancer. Our approach is divided into two steps: the first issue aims at highlighting specific spectroscopic markers of the bronchial cancer permitting to detect unambiguously the presence of cancer cells. The second step relies on establishing a chemometric model able to estimate the tumor invasivity of these malignant cells For our approach, we used 4 different bronchial cellular lines displaying different in vitro invasive properties assessed by a modified Boyden chamber assay : the non invasive cell line 16HBE used as a control, the moderate invasive cell line Beas2B and the two highly invasive cell lines BZR and BZRT33. Four samples of each cell line were cultured and embedded in paraffin wax. Slices of 10 μm were prepared on CaF2 windows suitable for IR measurements. The infrared acquisitions were performed with an imager (Bruker, Germany) equipped with a Focal Plane Array detector allowing to image large tissue areas with a spatial resolution of a few micrometers. The IR spectra were processed using chemometric and statistical multivariate treatments. A first stage permitted to correct spectral interferences originated from the paraffin and optical effects. Then, supervised models were established by means of PLS-DA (Partial Least Square Discriminant Analysis) method. A first model, based on sparse-PLS method, was optimized to highlight spectroscopic markers specific of the normal and cancerous states; this model has proved effective in terms of sensibility (96%) and specificity (90%). Based on these promising results, the study will be pursued by the analysis of tissue samples from biopsies and tumor samples. Subsequently, the next investigation will rely on the construction of a second model to model and quantify the aggressiveness level of the cell lines. Citation Format: Vincent D. Gaydou, Myriame Polette, Cyril Gobinet, Claire Kileztky, Michel Manfait, Philippe Birembaut, Olivier Piot. Infrared spectral diagnosis for predictive cancer medicine: application to the early diagnosis and prognosis of preinvasive bronchial intraepithelial lesions. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 212. doi:10.1158/1538-7445.AM2015-212
Sexual function in endometriosis patients and their partners: effect of the disease and consequences of treatment
Authors: Nicola Pluchino, Jean-Marie Wenger, Patrick Petignat, Reshef Tal, Mylene Bolmont, Hugh S. Taylor, Francesco Bianchi-Demicheli
Journal: Human Reproduction Update (2016)

Sexual function is an important aspect of health and quality of life and is influenced by both medical conditions and health-care interventions, especially when gynecologic disorders are involved. Coital pain is among the main factors that affect sexual functioning, and this symptom is reported by almost half of women suffering from endometriosis. However, sexuality is a complex phenomenon driven by social, psychological and biological/hormonal factors and the presence of endometriosis might further affect domains of sexual function and the quality of a sexual relationship.The objective of this report is to review the current state of knowledge on the impact that endometriosis and its treatments have on the sexual function of women and their sexual partners.A systematic literature search was performed to identify studies evaluating sexual function in endometriosis patients, and a narrative analysis of results is presented. The review discusses relevant quantitative and qualitative studies analyzing the effect of endometriosis and its hormonal and surgical treatments on measures of sexual function and quality of sexual relationship.Endometriosis negatively affects different domains of sexual function, and the presence of dyspareunia is not the only determinant of sexual health in these women. Chronic pelvic pain, advanced stages of disease and the presence of physical and mental comorbidities affect sexual function, as well as personality traits and women's expectations. Although a number of studies have evaluated the effect of surgery and hormonal treatment on deep dyspareunia, overall sexual function and quality of the relationship with the partner are often under-investigated.Multiple clinical and personal determinants affect sexual function in women with endometriosis, with potentially negative consequences on the sexual function of partners and quality of the relationship. Additional prospective and longitudinal investigations are warranted using specific instruments to analyze biopsychosocial variables of sexual pain in endometriosis patients and the effects that actual treatments have on measures of quality of sexual function and relationship.
Increased Alternative Macrophage-2 (M2) Polarization with Trib1 Gene over Expression in Myeloma Patients with Progressive Disease and Jak2 Inhibitors Reduce M2 Polarization
Authors: Haiming Chen, Mingjie Li, Eric Sanchez, Abigail Gillespie, Cathy Wang, Tiffany Lee, Suzie Vardanyan, Jason Nosrati, Jasmin Cao, Michael Zahab, Puja Mehta, Gigi Garzio, George Tang, James R. Berenson
Journal: Blood (2015)
Incidence and risk factors of blood splatter in dermatological surgery: how protective are full facial masks?
Authors: S. Aguilar‐Duran, A. Panthagani, L. Naysmith, S. A. Holme
Journal: British Journal of Dermatology (2016)

Blood splatter in dermatological surgery is common, with an estimated incidence of 33% in the operator and 15% in the assistant operator.1 The use of masks with visor has increased in recent years to improve mucocutaneous protection against blood-borne virus transmission. In spite of this, there are no clear recommendations on when to use them and their efficacy.

This article is protected by copyright. All rights reserved.
P1352 : Pharmacokinetics and pharmacology of RG-101, a novel GalNAc-conjugated oligonucleotide targeting microrna-122, in healthy volunteers
Authors: K. Liu, S. Neben, None N.W.Gibson, P. Grint, A. van Vliet, S. Hadi, M. de Vree, M. van der Ree, H. Reesink
Journal: Journal of Hepatology (2015)
Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score
Authors: Jose Falantes, Sylvain Thepot, Lisa Pleyer, Luca Maurillo, Violeta Martínez-Robles, Raphaël Itzykson, Joan Bargay, Reinhard Stauder, Adriano Venditti, Maria Pilar Martinez, Valerie Seegers, Maria Angeles Foncillas, Sonja Burgstaller, Claude Gardin, Pau Montesinos, Pellegrino Musto, Richard Greil, Miguel Sanz, Pierre Fenaux, Fernando Ramos
Journal: Blood (2015)
Studying with the enemy
Authors: Enrique Soto Pérez de Celis
Journal: BMJ (2003)

Over the past 10 months, my girlfriend has had rectal cancer, diabetes, amebiasis, mesenteric ischemia, and even severe acute respiratory syndrome. No, she does not have familial polyps, she is not obese, she is not a senior citizen, and she has never been to Beijing. She is just a medical student.

It all started a year ago when she began her clinical courses. After taking microbiology, she had an acute case of shigellosis. A day after passing endocrinology, she fell ill with a pheochromocytoma. And three months ago, having finished gastroenterology, her rectum had a malignant neoplasm, a parasitic infection, and haemorrhoids.

To me, this seemed like regular hypochondria. However, as the days (and the courses) flew by, I became worried about her mental health. She spent hours reading, trying to figure out what terrible microbe was behind her headache. I had to check her blood pressure, her tonsils, her tympanum, and her heartbeat every time she had diarrhoea. One day, when a rash appeared on her forearm, she dramatically …
Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.
Authors: Elia Seguí, Laia Paré, Barbara Adamo, Estela Pineda, Mercedes Marín-Aguilera, Òscar Reig, Javier Garcia Corbacho, Montserrat Munoz, Manel Juan, Victoria Sanchez, Margarita Viladot, Carme Font, Daniel Benitez, Cristina Nadal, Nuria Vinolas, Núria de la Iglesia, Begona Mellado, Juan Maurel, Noemi Reguart, Aleix Prat
Journal: Journal of Clinical Oncology (2016)

3033 Background: Immune infiltration predicts survival in particular cancer-types. However, differences in immune profiling and associations with patient outcomes among multiple cancer-types have not been fully explored. Methods: Clinical and RNA-seq data from 9,761 tumors representing 30 cancer-types were obtained from TCGA project. The expression of 35 immune-related gene signatures tracking various cell-types was evaluated, including PD1, CTLA4, CD8A and CD4 genes. Association of each signature with overall survival (OS) was evaluated using Cox models. Correlations between each signature and the overall response rates (ORR) following anti-PD1/PDL1 monotherapy in each cancer-type (as reported in the literature) were evaluated across 16 cancer-types. Results: In the combined dataset, 15 out of 35 signatures (43%) mostly tracking cytotoxic T-cell response (e.g. CD8-T-cell, PD1 and CD8A) were highly correlated (mean coefficient [cc] = 0.69). The top 5 cancer-types with the highest percentages of samples expressing cytotoxic T-cell response signatures were lung adenocarcinoma (LUAD), thymoma, testicular cancer, melanoma and basal-like breast cancer. The top 5 cancer-types with the lowest percentages were chromophobe renal cell, pheochromocytoma/paraganglioma, prostate cancer, adrenocortical cancer and uveal melanoma. In terms of OS, expression of T-cell response signatures (as a continuous variable) was consistently associated with better outcomes in melanoma, endometrial adenocarcinoma, head and neck carcinoma, hepatocarcinoma, bladder cancer and LUAD, and with worse outcomes in low grade glioma, uveal melanoma, glioblastoma and clear cell renal carcinoma. Finally, high expression of CD8A gene, CD8-T-cell signature and PD1 gene was found highly correlated (cc = 0.68, 0.62 and 0.77, P< 0.001) with ORR following anti-PD1/PDL1 therapy. Conclusions: Significant differences in the expression of immune signatures exist within and across cancer-types. Whereas the association of cytotoxic T-cell response with OS might be dependent on cancer-type, response to anti-PD1/PDL1 checkpoint inhibitors seems associated with the absolute levels of pre-existing cytotoxic T-cell response.
Exome Sequencing Of Paired Chronic-Blast Phase Samples In Myeloproliferative Neoplasms Reveals High Frequency Of Rare Germline Sequence Variants In TYK2 and Novel Blast Phase-Restricted Mutations
Authors: Isabell Schulze, Terra L Lasho, ASCP, Georg Evers, Gabriela B. Thoennissen, Hans-Ulrich Klein, Martin Dugas, Wolfgang E. Berdel, Carsten Müller-Tidow, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2013)
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.
Authors: Omid Hamid, John A. Thompson, Adi Diab, Willeke Ros, Ferry Eskens, Candy Bermingham, Cyril Konto, Hua Long, Ken Liao, Bishu J Ganguly, Catherine Fleener, Susan Pleasic-Williams, Pamela D. Garzone, Premal H. Patel, Tenshang Joh, Dimitry S. A. Nuyten, Anthony B. El-Khoueiry
Journal: Journal of Clinical Oncology (2016)

3079 Background: Stimulating effector T cells is an attractive anti-cancer therapeutic strategy. PF-8600 is a novel fully human IgG2 agonistic mAb specific for human OX40, a tumor necrosis factor receptor expressed primarily on activated T cells. PF-8600 provides an immunotherapeutic approach distinct to PD-1 and CTLA-4. A FIH phase 1 study of PF-8600 to investigate the safety, maximum-tolerated dose, PK, immunomodulation and preliminary antitumor activity is on-going in pts with refractory melanoma, head and neck squamous cell, renal cell and hepatocellular carcinoma. Methods: PF-8600 was administrated intravenously every 14 days at doses 0.01 - 0.3 mg/kg. 28-day dose-limiting toxicity (DLT) was evaluated using a modified Toxicity Probability Interval design. PF-8600 PK profiling was completed during cycles 1 and 3. Starting at 0.1 mg/kg, each dose level is expanded to 10 patients for paired tumor biopsy assessments. Free and total OX40 receptor and markers of T cell proliferation (Ki67) were measured on CD4 and CD8 naïve, central and effector memory cells. Results: As of 02 Nov 2015, 9 pts were enrolled in the dose-escalation phase of the study: 0.01 mg/kg (2pts), 0.1 mg/kg (3 pts) and 0.3 mg/kg (4pts). No DLT, drug-related serious Adverse Events (AEs), immune related AEs or drug-related grade 3-5 AEs were observed. The most frequent drug-related AE was grade 2 fatigue (33.3%). 4 patients experienced best ORR of stable disease (RECIST), and 2 previously immunotherapy-treated patients have been on study for > 6 months. In the periphery, PF-8600 exhibited full target receptor occupancy and enhanced memory T cell proliferation at 0.3 mg/kg. Exposure (AUCτ ) increased with increasing doses during cycle 1. Conclusions: These preliminary results demonstrate that PF-8600, an agonistic OX40 mAb, is safe up to 0.3 mg/kg, and biomarker endpoints are met. The highest planned dose cohorts (1.5 and 3 mg/kg) are enrolling and will be presented. Clinical trial information: NCT02315066.
Response to: “Prognostic relevance of epilepsy at presentation in lower-grade gliomas”
Authors: Sharon Berendsen, Tom J. Snijders, Pierre A. Robe
Journal: Neuro-Oncology (2016)

Additional criteria apply.Please refer to protocol 14379-201 for full inclusion and exclusion criteria.† Patients can participate if they had some skin cancers, superficial bladder cancer (cancer that was only on the surface of the lining of the bladder), or carcinoma in situ (cancer that had not spread) of the cervix or breast that had been cured.
Do FMS-like Tyrosine Kinase 3 and Nucleophospmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?
Authors: Mehmet Gunduz, Pinar Ataca, Mehmet Ozen, Erden Atilla, Sinem Civriz Bozdag, Selami Kocak Toprak, Pervin Topcuoglu, Muhit Ozcan, Taner Demirer, Meral Beksac, Hamdi Akan, Gunhan Gurman, Osman Ilhan, Nahide Konuk, Onder Arslan
Journal: Blood (2014)
Prehospital Airway Management for Out-of-Hospital Cardiac Arrest—Reply
Authors: Kohei Hasegawa, Atsushi Hiraide, David F. M. Brown
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reduction in immunoglobulin (IVIG or anti D) use in patients with chronic immune thrombocytopenic purpura (ITP) receiving AMG 531
Authors: Vinod Pullarkat, Terry B. Gernsheimer, de Joseph Wolf, Troy H. Guthrie, Adrian Newland, Jeffrey S. Wasser, Solomon I. Hamburg, Sue Gao, Roy Stewart, Janet L. Nichol
Journal: Blood (2007)
Aspirin and Cancer Risk—Reply
Authors: Yin Cao, Andrew T. Chan
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Hematopoietic Progenitor Cell Counts Is a Useful Indicator To Determine Appropriate Time For Peripheral Blood Stem Cell Collection
Authors: Sun-Young Kong, Hyoeun Shim, Se-Na Lee, Jung-Hee Kong, Hyeon-Seok Eom, Byung-Kiu Park, Hyeon Jin Park, Tak Yun, Hyewon Lee, Yoon Kyung Song
Journal: Blood (2013)
Differential Functional Outcomes After Stimulation Via Innate Immunity Receptors In Chronic Lymphocytic Leukemia Subtypes Defined by the Molecular Features of the Immunoglobulin Receptor
Authors: Stavroula Ntoufa, Anna Vardi, Nikos Papakonstantinou, Achilles Anagnostopoulos, Vassiliki Aleporou-Marinou, Federico Caligaris-Cappio, Chrysoula Belessi, Paolo Ghia, Marta Muzio, Kostas Stamatopoulos
Journal: Blood (2010)
Correlation of stem cell marker nestin expression on circulating melanoma cells with extension of disease and survival.
Authors: A. Fusi, U. Reichelt, A. Busse, S. Ochsenreither, A. Rietz, M. Maisel, U. Keilholz
Journal: Journal of Clinical Oncology (2010)

8551 Background: Within circulating melanoma cells (CMCs) there may be a subset of cells with stem cell characteristics able to develop distant metastasis. We evaluated the presence of melanoma cells bearing stem cell phenotype in the bloodstream of patients (pts) with metastatic melanoma. Stem cell marker assessment included nestin (NES) and CD133. Methods: Twenty-five ml blood were collected after informed consent from 32 consecutive pts affected by metastatic uveal (n = 14) or cutaneous (n = 18) melanoma and from (n = 6) healthy volunteers according to ethically approved protocols. Blood was enriched for tumour cells by CD45 depletion of the non-melanoma cell fraction using a magnetic bead separation technique. Potential melanoma cells were identified using flow cytometry with the markers MELAN-A and HMB45. Multiparameter cytometry was carried out to co-stain with the combinations of CD133 and NES. Five tissue samples from metastatic lesions of five different pts were stained with the same antibodies by immunohistochemistry. Results: No cells positive for the melanocyte markers were detected in blood from volunteers. In pts MELANA and/or HMB45 positive cells were detected in 28 samples (87.5%). The absolute number of melanoma cells ranged from 0 to 1233 (median 53) per 10 mL of blood. NES expressing cells were more represented compared to CD133 expressing cells (median 18.0% [0.3%-85.1%] vs. median 0.1% [0%-23.4%]). Percentage of NES-positive cells correlated significantly with tumor burden (p = 0.01) and number of metastatic sites (p = 0.03), whereas percentage of CD133-positive cells and absolute total number of cells did not. Cox regression analysis revealed levels of LDH (HR: 12.8 [1.35-121.5]; p = 0.02), number of metastatic sites (HR 3.87 [1.66-9.03]; p = 0.02), tumor burden (HR 5.72 [1.57- 20.9]; p = 0.01) and high level of NES expression (HR 3.5 [0.92-13.6]; p = 0.04) to be factors related to shorter overall survival. CD133 and NES expression profiles on CMCs and in matched metastatic tissue were similar. Conclusions: Melanoma cells in peripheral blood expressed stem cell associated markers NES and CD133. Higher expression of NES on CMCs might represent an index of poor prognosis. No significant financial relationships to disclose.
Counterimmunoelectrophoresis and Bacterial Meningitis
Authors: John Eckfeldt
Journal: JAMA (1978)

To the Editor.—  Having just reviewed our experience with counterimmunoelectrophoresis (CIE), we read with interest the letter from Denis et al (238:1248, 1977) regarding CIE for the diagnosis of bacterial meningitis. Our observations are not in agreement with those of Denis et al, and the discrepancies have important clinical implications.  Our procedure employs an electrophoresis chamber and tris-barbital buffer (pH 8.8) in 1% agarose. The antisera we use are group B Streptococcus, Haemophilus influenzae type b, Neisseria meningitidis (groups A thru D and XYZ), and Streptococcus pneumoniae omnisera.  Our laboratory began doing CIE on CSF samples shortly after the method was introduced for the diagnosis of bacterial meningitis. 1,2 During this time, it gradually became apparent that our experience did not support the early optimism expressed in the literature. Use of commercial reagents was initially considered to be responsible for the lack of positive results in our patient specimens, but
Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies
Authors: Mary E. Spilker, Xiaoying Chen, Ravi Visswanathan, Chandra Vage, Shinji Yamazaki, Gang Li, Judy Lucas, Erica L. Bradshaw-Pierce, Paolo Vicini
Journal: Clinical Cancer Research (2016)

Purpose: The translation of nonclinical oncology studies is a subject of continuous debate. We propose that translational oncology studies need to optimize both pharmacokinetic (drug exposure) and pharmacodynamic (xenograft model) aspects. While improvements in pharmacodynamic translatability can be obtained by choosing cell lines or patient-derived xenograft models closer to the clinical indication, significant ambiguity and variability exists when optimizing the pharmacokinetic translation of small molecule and biotherapeutic agents.Experimental Design and Results: In this work, we propose a pharmacokinetic-based strategy to select nonclinical doses for approved drug molecules. We define a clinically relevant dose (CRD) as the dosing regimen in mice that most closely approximates the relevant pharmacokinetic metric in humans. Such metrics include area under the time-concentration curve and maximal or minimal concentrations within the dosing interval. The methodology is applied to six drugs, including targeted agents and chemotherapeutics, small and large molecules (erlotinib, dasatinib, vismodegib, trastuzumab, irinotecan, and capecitabine). The resulting efficacy response at the CRD is compared with clinical responses.Conclusions: We conclude that nonclinical studies designed with the appropriate CRDs of approved drug molecules will maximize the translatability of efficacy results, which is critical when testing approved and investigational agents in combination. Clin Cancer Res; 23(4); 1080-90. ©2016 AACR.